Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Colorcon
Merck
Daiichi Sankyo
UBS
McKesson
Julphar
Dow
Cipla

Generated: December 12, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TAMSULOSIN HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Tamsulosin Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00090103 Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment Completed GlaxoSmithKline Phase 3 This study will investigate the efficacy and safety of treatment with dutasteride and tamsulosin, administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic Benign Prostatic Hyperplasia (BPH). Study visits are every 3 months for up to 4 years (18 clinic visits). Transrectal ultrasound (TRUS) is done annually.
NCT00147654 Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction Completed Pfizer Phase 4 The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge incontinence (UUI), with or without bladder outlet obstruction (BOO).
NCT00151567 Evaluation of Tamsulosin in the Treatment of Ureteral Stones Completed Ministry of Health, France Phase 3 Ureteral stones have an important place in daily urological practice, usually causing acute episodes of ureteral colic by obstructing the urinary tract. The aim of the study is to evaluate whether repeated administration of tamsulosin, a drug routinely used in the treatment of lower urinary tract symptoms, could lower the delay of elimination of the stone in patients with pelvis ureterolithiasis.
NCT00151567 Evaluation of Tamsulosin in the Treatment of Ureteral Stones Completed Yamanouchi Phase 3 Ureteral stones have an important place in daily urological practice, usually causing acute episodes of ureteral colic by obstructing the urinary tract. The aim of the study is to evaluate whether repeated administration of tamsulosin, a drug routinely used in the treatment of lower urinary tract symptoms, could lower the delay of elimination of the stone in patients with pelvis ureterolithiasis.
NCT00151567 Evaluation of Tamsulosin in the Treatment of Ureteral Stones Completed Rennes University Hospital Phase 3 Ureteral stones have an important place in daily urological practice, usually causing acute episodes of ureteral colic by obstructing the urinary tract. The aim of the study is to evaluate whether repeated administration of tamsulosin, a drug routinely used in the treatment of lower urinary tract symptoms, could lower the delay of elimination of the stone in patients with pelvis ureterolithiasis.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Tamsulosin Hydrochloride

Condition Name

Condition Name for Tamsulosin Hydrochloride
Intervention Trials
Prostatic Hyperplasia 29
Benign Prostatic Hyperplasia 26
Lower Urinary Tract Symptoms 12
Healthy 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tamsulosin Hydrochloride
Intervention Trials
Prostatic Hyperplasia 66
Hyperplasia 64
Lower Urinary Tract Symptoms 23
Urinary Retention 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tamsulosin Hydrochloride

Trials by Country

Trials by Country for Tamsulosin Hydrochloride
Location Trials
United States 194
Germany 41
Korea, Republic of 31
Italy 27
United Kingdom 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tamsulosin Hydrochloride
Location Trials
California 11
Texas 10
New York 10
Alabama 9
Florida 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tamsulosin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Tamsulosin Hydrochloride
Clinical Trial Phase Trials
Phase 4 38
Phase 3 34
Phase 2/Phase 3 2
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tamsulosin Hydrochloride
Clinical Trial Phase Trials
Completed 91
Recruiting 23
Unknown status 20
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tamsulosin Hydrochloride

Sponsor Name

Sponsor Name for Tamsulosin Hydrochloride
Sponsor Trials
GlaxoSmithKline 20
Boehringer Ingelheim 20
Astellas Pharma Inc 13
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tamsulosin Hydrochloride
Sponsor Trials
Industry 101
Other 78
U.S. Fed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Boehringer Ingelheim
Express Scripts
McKesson
Julphar
Medtronic
Queensland Health
Chinese Patent Office
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.